David Lee, CEO, Servier
David K. Lee is a seasoned veteran of the pharma industry dedicated to bringing innovative, responsible and life-changing products to patients. As CEO, David leads Servier Pharmaceuticals’ efforts to leverage Servier Group’s global portfolio and seek acquisitions, licensing deals and partnerships in the U.S. Under David’s leadership, the company has quadrupled its oncology portfolio and completed several business development and licensing agreements. Since its inception in 2018, the company’s growth has positioned Servier Pharmaceuticals as a leader in the oncology space, achieving successful and significant clinical trial results and tackling hard-to-treat cancers. Before becoming the CEO of Servier Pharmaceuticals, David held leadership positions at several industry-leading companies throughout his career, including Shire, Baxalta, and Novartis. David received his Bachelor of Science in Biochemistry from Harvard University and his Master of Business Administration from Harvard Business School.
